Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

Phase 2

• Conditions: T Cell Lymphoma; ALL, Adult and Pediatric; Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; DLBCL; Multiple Myeloma
• Interventions: Biological: AUTO CAR T cell therapy

• Registration Number: NCT03628612
• Lead Sponsor: Autolus Limited

Brief Summary

Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.

Detailed Description

The purpose of this study is to monitor all patients exposed to an AUTO CAR T cell therapy, for up to 15 years following their first AUTO CAR T cell therapy infusion to assess the risk of delayed treatment-related SAEs, adverse events of special interest (AESIs), monitor for emergence of replication competent retrovirus (RCR) or replication competent lentivirus (RCL), monitor for the emergence of a new malignancy associated with insertional mutagenesis (insertion site analysis), assess CAR transgene persistence and assess long-term efficacy. Monitoring of such long-term effects of AUTO CAR T cell therapy will help to further define the risk-benefit profile of these new CAR T cell therapies.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-07-07
• Study Start: 2018-08-02
• Study First Submitted QC: 2018-08-09
• Study First Posted: 2018-08-14
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-24
• Last Update Posted: 2024-06-26
• Primary Completion: 2043-07
• Study Completion: 2043-12

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Patients must have received an AUTO CAR T cell therapy on a clinical treatment study.
2. Patients must have provided informed consent for long-term follow-up study prior to participation.
3. Patients must be able to comply with the study requirements.

Read More

Exclusion Criteria

1. There are no specific exclusion criteria for this study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
AUTO CAR T cell therapy	AUTO CAR T cell therapy	Patients who received previous treatment with AUTO CAR T Cell Therapy

Primary Outcome Measures

Name	Time	Method
Incidence of Serious Adverse Events (SAE), new malignancies & adverse events of special interest (AESI) related to AUTO CAR T cell therapy	For up to 15 years	Monitoring of all SAEs / AESIs, including any new malignancy or new diagnosis of neurologic disorders, or other hematologic disorder, related to AUTO CAR T cell therapy.; Monitoring of all adverse events of special interest related to AUTO CAR T cell therapy infusion.

Secondary Outcome Measures

Name	Time	Method
Overall Survival following first AUTO CAR T cell therapy infusion.	Month 3, Month 6, Month 9, Month 12 during Year 1 following AUTO CAR T cell therapy infusion, then every 6 months up to Year 5, then yearly up to Year 15	Overall Survival following first AUTO CAR T cell therapy infusion.
Duration of response	Month 3, Month 6, Month 9, Month 12 during Year 1 following AUTO CAR T cell therapy infusion, then every 6 months up to Year 5, then yearly up to Year 15	Clinical efficacy of AUTO CAR T cell therapy in patients enrolled prior to disease progression.
Progression-free survival	Month 3, Month 6, Month 9, Month 12 during Year 1 following AUTO CAR T cell therapy infusion, then every 6 months up to Year 5, then yearly up to Year 15	Progression free survival following first AUTO CAR T cell therapy infusion.
Duration of supportive care	Month 3, Month 6, Month 9, Month 12 during Year 1 following AUTO CAR T cell therapy infusion, then every 6 months up to Year 5, then yearly up to Year 15	B-cell aplasia for patients treated with an AUTO CAR T cell therapy targeting a B-cell malignancy.
Testing for Insertional mutagenesis in case of a new malignancy	For up to 15 years	Insertional site analysis of samples to determine insertional mutagenesis as a potential cause / contributor in case of a new malignancy.
Proportion of patients with detectable replication-competent retrovirus (RCR) or lentivirus (RCL) from first AUTO CAR T cell therapy infusion	For up to 15 years	Monitor for the absence of detectable RCR or RCL after the first AUTO CAR T cell therapy infusion
Proportion of patients with detectable vector copy number (VCN) in peripheral blood	Month 3, Month 6, Month 9, Month 12 during Year 1 following AUTO CAR T cell therapy infusion, then every 6 months up to Year 5, then yearly up to Year 15	Blood sample collection for VCN measurement to detect persistence of CAR transgene(s)

Trial Locations

Locations (8)

University of Miami; 🇺🇸 Miami, Florida, United States

University College London Hospitals NHS Foundation Trust; 🇬🇧 London, United Kingdom

St David's South Austin Medical Center; 🇺🇸 Austin, Texas, United States

Washington University in St. Louis; 🇺🇸 Saint Louis, Missouri, United States

Queen Elizabeth University Hospital; 🇬🇧 Glasgow, United Kingdom

Manchester Royal Infirmary Hospital; 🇬🇧 Manchester, United Kingdom

Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust; 🇬🇧 Newcastle Upon Tyne, United Kingdom

Royal Manchester Children's Hospital; 🇬🇧 Manchester, United Kingdom